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The coiled-coil domain of the tripartite motif (TRIM) family protein TRIM5α is required for trimerization and function as an antiretroviral
restriction factor. Unlike the coiled-coil regions of other related TRIM proteins, the coiled coil of TRIM5α is not sufficient for multimerization.
The linker region between the coiled-coil and B30.2 domains is necessary for efficient TRIM5α trimerization. Most of the hydrophilic residues
predicted to be located on the surface-exposed face of the coiled coil can be altered without compromising TRIM5α antiviral activity against
human immunodeficiency virus (HIV-1). However, changes that disrupt TRIM5α trimerization proportionately affect the ability of TRIM5α to
bind HIV-1 capsid complexes. Therefore, TRIM5α trimerization makes a major contribution to its avidity for the retroviral capsid, and to the
ability to restrict virus infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: TRIM5α; HIV-1; Retroviral capsid; Coiled-coil domain; TrimerizationIntroduction
The retroviral restriction factor TRIM5α is a member of a
family of proteins that contain a tripartite motif, hence the
designation TRIM (Reymond et al., 2001). The tripartite motif
includes a RING domain, B-box 2 domain, and coiled-coil (cc)
domain; TRIM proteins have also been called RBCC proteins.
TRIM proteins exhibit the propensity to form cytoplasmic or
nuclear bodies (Reymond et al., 2001). Many cytoplasmic
TRIM proteins contain a C-terminal B30.2 or SPRY domain.
Differential splicing of the TRIM primary transcripts gives rise
to the expression of several isoforms of the protein products.
TRIM5α is the largest TRIM5 isoform (∼493 amino acid
residues) and contains the B30.2(SPRY) domain.
The TRIM5α proteins of different primate lineages mediate
early blocks to infection by particular retroviruses. For example,
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doi:10.1016/j.virol.2006.05.017immunodeficiency virus (HIV-1), whereas human TRIM5α
(TRIM5αhu) only modestly blocks HIV-1 infection but
efficiently restricts N-tropic murine leukemia virus (N-MLV)
infection (Hatziioannou et al., 2004; Keckesova et al., 2004;
Perron et al., 2004; Yap et al., 2004; Stremlau et al., 2004). The
B30.2(SPRY) domain of rhesus monkey TRIM5α is essential
for anti-HIV-1 activity (Stremlau et al., 2004). Several lines of
evidence hint that TRIM5α associates directly or indirectly with
the restricted retroviral capsid. First, the viral determinants of
susceptibility to restriction map to the capsid protein (Stremlau
et al., 2004). Second, when introduced into cells, assembled
and proteolytically processed capsids of virus-like particles, but
not individual capsid proteins, can compete for the restriction
factor(s) (Bieniasz, 2003; Goff, 2004; Stoye, 2002). Recently,
the B30.2(SPRY) domains have been shown to be essential for
TRIM5αhu and TRIM5αrh association with N-MLV and HIV-1
capsid complexes, respectively (Sebastian and Luban, 2005;
Stremlau et al., 2006).
Coiled-coil domains have been implicated in the ability of
TRIM proteins to form homo-oligomers (Reymond et al.,
2001). Coiled-coil domains from various proteins typically
exhibit a seven-residue repeat (abcdefg), where a and d
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homo-oligomerization (Harbury et al., 1993, 1995; Lumb and
Kim, 1995; Lupas et al., 1991). The other residues, which are
exposed on the assembled coiled coil, tend to be polar residues.
Sequence variation among coiled coils determines oligomeriza-
tion states and specific functions. Structural predictions suggest
that the coiled coils of TRIM proteins exhibit a propensity to
form both dimers and trimers (Harbury et al., 1993, 1995; Lupas
et al., 1991). Oligomerization has been shown to be important
for the function of the nuclear TRIM28 (KAP-1) protein (Peng
et al., 2000, 2002). The coiled-coil domain of TRIM5 was
shown to be necessary for multimerization (Javanbakht et al.,
2005; Perez-Caballero et al., 2005). Recently, TRIM5α proteins
from different species have been shown to form trimers (Mische
et al., 2005). Deletion of the TRIM5αrh coiled coil disrupted the
interaction with HIV-1 CA–NC complexes (Stremlau et al.,
2006). Trimerization may allow TRIM5α to interact with sites
on the surface lattice of the retroviral capsid that exhibit trimeric
pseudosymmetry (Mische et al., 2005). Significant gains in
avidity would accrue to the interactions of two oligomeric
complexes with compatible symmetry.
Here, we study the requirements for TRIM5α trimerization
and define sequences flanking the coiled-coil region that
contribute to oligomerization. We study the impact of
TRIM5α oligomerization on association with the viral capsid
protein and the ability to mediate the restriction of retroviral
infection.
Results
Contribution of the TRIM5αrh coiled-coil domain to
trimerization and function
Secondary structure predictions (Lupas et al., 1991) indicate
that the TRIM5α coiled-coil (CC) domain consists of two
regions (CCA and CCB), each of which exhibits a strong
propensity to form a coiled coil, separated by a spacer region
(Fig. 1A). To investigate the contribution of the TRIM5αrh CC
domain to oligomerization and function, we generated several
mutants with deletions affecting this domain (Fig. 1A). The
wild-type and mutant TRIM5αrh proteins have an influenza
hemagglutinin (HA) epitope tag at their carboxyl termini. In the
TRIM5αrhΔCC mutant, the entire CC domain is deleted. In the
TRIM5αrh ΔCC GCN4, the deleted TRIM5αrh CC domain is
replaced by a heterologous trimeric coiled coil derived by
modification of the GCN4 transcription factor (Harbury et al.,
1993; Lumb and Kim, 1995). This GCN4 trimeric CC domain
has been shown to assist or promote the trimerization of other
proteins (Weissenhorn et al., 1997; Yang et al., 2002, 2005). In
the TRIM5αrh ΔCCA and ΔCCB mutants, the CCA and CCB
predicted coiled coils are respectively deleted. The TRIM5αrh
CC NT and CC CT mutants contain each half of the TRIM5αrh
protein, with the CCA region in the CC NT mutant and the CCB
region in the CC CT mutant.
To examine the expression and oligomerization state of the
mutant TRIM5αrh proteins, cross-linking with increasing
concentrations of ethylene glycol-bis(succinimidyl succinate)(EGS) was employed. The wild-type TRIM5αrh protein was
cross-linked into a 160 kDa species, consistent with a trimer
(Fig. 1B). The TRIM5αrh ΔCC mutant, by contrast, did not
exhibit higher-order forms upon cross-linking. The trimeric
GCN4 motif in the TRIM5αrh ΔCC GCN4 mutant restored the
ability of the protein to oligomerize into trimers, with only
slightly decreased efficiency compared to the wild-type
TRIM5αrh protein. Deletion of the CCA region dramatically
reduced the efficiency of trimer formation, although higher-
order forms were apparent after cross-linking. The oligomeri-
zation of the TRIM5αrh ΔCCB mutant was severely compro-
mised, compared with that of the wild-type TRIM5αrh protein.
Neither of the TRIM5αrh CC NT or CC CT mutants exhibited
evidence of oligomerization in cross-linking experiments (Fig.
1B). In coimmunoprecipitation experiments, neither of these
mutants demonstrated the ability to associate with each other or
with the wild-type TRIM5αrh protein (Fig. 1C). We conclude
that both the CCA and CCB elements of the TRIM5αrh CC
domain are critical for efficient trimerization.
The effect of changes in the TRIM5αrh CC and flanking
regions on the subcellular localization of the protein was
examined by staining Cf2Th cells stably expressing these
variants with an antibody directed against the HA epitope tag
(Fig. 1D). The wild-type TRIM5αrh protein was diffusely
located throughout the cytoplasm and also concentrated in
cytoplasmic bodies, as previously described (Javanbakht et al.,
2005; Perez-Caballero et al., 2005). The TRIM5αrh mutants
examined, which have deletions of the CC or adjacent linker 2
domain, exhibited diffuse cytoplasmic staining, but did not
localize to cytoplasmic bodies (Fig. 1D). We conclude that the
TRIM5αrh CC and linker 2 domains are not required for
cytoplasmic localization, but may influence TRIM5αrh incor-
poration into cytoplasmic bodies, perhaps through a contribu-
tion to multimerization.
The ability of some of the TRIM5αrh variants to inhibit HIV-
1 infection was studied. Cf2Th cells expressing these variants or
transduced with the empty LPCX vector were challenged with
VSV G glycoprotein-pseudotyped recombinant HIV-1 expres-
sing green fluorescent protein (GFP), and GFP-positive cells
were scored (Fig. 1E). Cells expressing wild-type TRIM5αrh
protein potently resisted HIV-1 infection, whereas cells
expressing the other TRIM5αrh variants tested were infected
comparably to the control cells transduced with the empty
LPCX vector. Thus, the CC domain is apparently important for
the antiviral function of TRIM5αrh.
Definition of the minimum TRIM5α regions required for
trimerization
To examine the minimum sequences required for trimeriza-
tion of TRIM5α and other TRIM proteins, the CC domains of a
variety of TRIM family proteins were expressed independently
of the rest of the protein. As a control, the GCN4 trimerization
domain was expressed. This GCN4 protein and the coiled-coil
domains of human TRIM6, TRIM21, TRIM27, and TRIM1 all
exhibited the ability to form oligomers (Fig. 2). The TRIM6 and
TRIM21 coiled coils formed mostly dimers, whereas dimeric
Fig. 1. Effect of TRIM5αrh coiled-coil deletions on oligomerization and antiretroviral function. (A) The wild-type TRIM5αrh protein is depicted in the top figure. The
numbers of the amino acid residues at the boundaries of the TRIM5αrh domains are shown. The carboxyl terminus of the protein contains an influenza hemagglutinin
(HA) epitope tag. The two predicted alpha-helical coils (CCA and CCB) in the TRIM5α coiled-coil (CC) domain are shown. The elements of the TRIM5αrh protein
included in each of the constructs are depicted by a solid line. GCN4 represents the trimeric GCN4 coiled coil (Reymond et al., 2001). (B) Lysates from 293T cells
expressing wild-type and mutant TRIM5αrh proteins were cross-linked with increasing concentrations of ethylene glycol-bis(succinimidyl succinate) (EGS) and were
subjected to Western blotting with an anti-HA antibody. (C) 293T cell lysates were used for immunoprecipitation by the anti-V5 antibody. The precipitates were then
Western blotted with an anti-V5 antibody (upper panel) or an anti-HA antibody (lower panel). (D) Cf2Th cells stably expressing the HA-tagged wild-type or mutant
TRIM5αrh proteins were fixed and stained using a FITC-conjugated anti-HA antibody, as described in Materials and methods. Representative confocal microscopic
images of the Cf2Th cells expressing the indicated wild-type or mutant TRIM5αrh-HA proteins are shown. (E) Cf2Th cells expressing the wild-type and mutant
TRIM5αrh proteins, or control Cf2Th cells transduced with the empty pLPCX vector (Vector), were incubated with various amounts of HIV-1-GFP. Infected, GFP-
positive cells were counted by FACS. The results of a typical experiment are shown. Similar results were obtained in three independent experiments.
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237H. Javanbakht et al. / Virology 353 (2006) 234–246and trimeric forms of the TRIM27 and TRIM1 coiled coils
were evident after cross-linking. By contrast, the coiled-coil
regions of TRIM5αhu and TRIM5αrh did not exhibit any
higher-order forms indicative of oligomerization after cross-
linking. Likewise, the coiled-coil domain of TRIMCyp, aTRIM5 derivative in owl monkeys (Nisole et al., 2004; Sayah
et al., 2004), migrated as a monomer after EGS cross-linking
(Fig. 3A). These results suggest that the TRIM5 coiled coil,
unlike that of other TRIM proteins, is not sufficient for
oligomerization.
Fig. 2. Oligomerization of TRIM coiled-coil domains. Lysates from 293Tcells expressing the coiled-coil domains from the indicated TRIM proteins or from the trimeric
GCN4 protein (Reymond et al., 2001) were cross-linked with increasing concentrations of EGS and were subjected to Western blotting with an anti-V5 antibody.
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tion, we used cross-linking analysis to study TRIM5αrh variants
that contained the coiled coil and N- or C-terminal flanking
sequences (see Fig. 1A). A construct (TRIM5αrh B-box-CC)
containing only the B-box 2 and CC domains was mostly
monomeric, although very high-order forms could be detected
(Fig. 3A). The CC-L2 constructs, which contain the CC domains
of either TRIM5αrh or TRIMCyp and the linker (Linker 2)
between the CC and B30.2 domains, were cross-linked into stable
dimers and trimers (Fig. 3A). When coexpressed with wild-type
TRIM5αrh, the CC-L2 protein, but not the CC protein without the
L2 linker, was able to coprecipitate TRIM5αrh (Fig. 3B). The
addition of the L2 region also promoted the appearance of dimers
and trimers after cross-linking in the context of the TRIM5αrh
RBCC protein, which contains the RING, B-box 2 and CC
domains (Fig. 3C). Deletion of the L2 region from the complete
TRIM5αrh protein eliminated the formation of trimers (see
TRIM5αrh Δ235–297 in Fig. 3D). The L2 sequences from
residues 235–247 could be removed with only a small reduction
in the efficiency of trimer formation. The TRIM5αrh Δ235–247
protein exhibited a slight but reproducible ability to inhibit HIV-1
infection (Fig. 3E). Other deletions in L2 resulted in a significant
reduction (TRIM5αrh Δ235–258) or complete loss (TRIM5αrh
Δ258–297) of trimerization. These L2-deleted TRIM5αrh
mutants exhibited no anti-HIV-1 activity (Fig. 3E). These results
indicate that the L2 linker between the CC and B30.2 domains of
TRIM5αrh contributes to the efficiency of trimerization and
antiviral activity.
Functionally defective mutants of TRIM5αrh with deleted N-
or C-terminal domains often exhibit dominant-negative activity(Javanbakht et al., 2005; Perez-Caballero et al., 2005). To assess
potential dominant-negative activity of the TRIM variants
studied above, they were coexpressed with wild-type TRIM5αrh
or TRIMCyp in Cf2Th cells, which were subsequently
challenged with HIV-1-GFP (Fig. 4A). The cells expressing
the coiled coils of TRIM5αrh, TRIM5αhu, TRIM1, TRIM21 and
TRIM27 were more susceptible to HIV-1 infection than the
control cells expressing only TRIM5αrh or TRIMCyp (Fig. 4B).
We also tested potential dominant-negative activity by tran-
siently expressing some of the TRIM5α variants in 293T cells
stably expressing the wild-type TRIM5αrh protein. The
previously characterized (Javanbakht et al., 2005) dominant-
negative mutant TRIM5αrh Δ132 was included in the experi-
ment as a positive control, and the trimeric GCN4 protein was
included as a negative control. In this system, restriction ofHIV-1
infection by the wild-type TRIM5αrh protein was not affected by
expression of the GCN4 trimer or by transductionwith the empty
LPCX vector (Fig. 4C). HIV-1 restriction was partially relieved
by expression of the TRIM5αrh RBCC (which lacks the B30.2
(SPRY) domain), TRIM5αrh Δ132 (which lacks the RING
domain), TRIM5αrh ΔCC (which lacks the coiled coil), and
TRIM5αrh CC, the coiled coil of TRIM5αrh. These results
indicate that no single domain of TRIM5αrh is absolutely
required for some degree of dominant-negative activity.
Phenotypic effects of amino acid changes in the TRIM5αrh
coiled coil
Based on models of the TRIM5αrh coiled coil (Lupas et al.,
1991), we identified amino acid residues predicted to be on the
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of these residues should only minimally affect the ability of the
CC to oligomerize. Hydrophilic residues in the TRIM5αrh CC
were altered individually or in pairs to alanine, and the mutantFig. 3. Oligomerization of TRIM5 and TRIMCyp variants. (A) Lysates from 293T ce
with increasing concentrations of EGS and were subjected to Western blottin
immunoprecipitation by an anti-V5 antibody. The precipitates were Western blotted
panel). (C and D) Lysates from 293T cells expressing the indicated TRIM5αrh variant
Western blotting with an anti-HA antibody. (E) Cf2Th cells expressing the wild-type a
LPCX vector (Vector), were incubated with various amounts of HIV-1-GFP. Infected
are shown. Similar results were obtained in three independent experiments.proteins were expressed stably in Cf2Th cells. Expression of all
of the mutant proteins was comparable to that of the wild-type
TRIM5αrh protein (data not shown). The Cf2Th cells expressing
the wild-type and mutant TRIM5αrh proteins were challengedlls expressing the indicated variants of TRIMCyp or TRIM5α were cross-linked
g. (B) 293T cell lysates expressing the indicated proteins were used for
with either an anti-V5 antibody (upper panel) or an anti-HA antibody (lower
s were cross-linked with increasing concentrations of EGS and were subjected to
nd mutant TRIM5αrh proteins, or control Cf2Th cells transduced with the empty
, GFP-positive cells were counted by FACS. The results of a typical experiment
Fig. 3 (continued).
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in the hydrophilic CC residues restricted HIV-1 infection as
efficiently as the wild-type TRIM5αrh protein (Fig. 5A, upper
panel). The TRIM5αrh E197A/E198A, and E220A/E222A
mutants restricted HIV-1 infection less efficiently than the
wild-type protein. These mutants exhibited a degree of
trimerization comparable to that of wild-type TRIM5αrh (Fig.
5B). Thus, most of the hydrophilic residues in the TRIM5αrh CC
are not required for efficient anti-HIV-1 function.
We next altered TRIM5αrh CC residues predicted to be
situated on the hydrophobic surface thought to be involved in
oligomeric interactions (Harbury et al., 1993, 1995; Lumb and
Kim, 1995; Lupas et al., 1991). Three residues, alanine 137,
leucine 202 and methionine 223, were altered to a charged
(lysine) residue. Cf2Th cells stably expressing comparable
levels of the wild-type and mutant proteins were challenged
with HIV-1-GFP, and cross-linker analysis was performed to
assess the ability of the mutants to oligomerize. The TRIM5αrh
A137K and M223K mutants exhibited wild-type levels of
trimerization and HIV-1-restricting ability (Figs. 5A and B). By
contrast, the ability of the TRIM5α L202K mutant to trimerize
and restrict HIV-1 infection was severely attenuated compared
with that of the wild-type TRIM5αrh protein. These results are
consistent with the apparent dependence of TRIM5αrh oligo-
merization on the CCB region.
Relationship between TRIM5αrh trimerization and HIV-1
capsid binding
TRIM5αrh trimerization has been suggested to facilitate
multivalent association with the HIV-1 capsid (Mische et al.,
2005). To investigate the contribution of trimerization to theinteraction of TRIM5αrh with the HIV-1 capsid, we utilized a
recently established capsid-binding assay (Stremlau et al.,
2006) to evaluate the TRIM5αrh mutants with alterations in the
CC or flanking regions. In this assay, HIV-1 capsid-like
complexes are assembled in vitro from purified HIV-1 capsid-
nucleocapsid (CA–NC) protein (Ganser et al., 1999). After
incubation with TRIM5αrh-containing cell lysates, the CA–
NC complexes are allowed to sediment through 70% sucrose
cushions. The TRIM5αrh protein cosediments through the
sucrose cushion only if it binds the HIV-1 CA–NC complexes
(Stremlau et al., 2006).
As expected, wild-type TRIM5αrh efficiently bound the
HIV-1 CA–NC complexes (Fig. 6A), whereas the TRIM5αrh
proteins with CC deletions did not. Even the trimeric TRIM5αrh
ΔCC GCN4 protein failed to interact detectably with the HIV-1
capsid-like complexes. Although the functional TRIM5αrh
A137K and M223K mutants bound the HIV-1 CA–NC
complexes as efficiently as the wild-type protein, the binding
of the TRIM5αrh L202K mutant was significantly less efficient
(Fig. 6B). The E197A/E198A and E220A/E222A mutants,
which restricted HIV-1 infection slightly less efficiently than
wild-type TRIM5αrh, bound HIV-1 CA–NC complexes
comparably to wild-type TRIM5αrh (data not shown). Changes
in the L2 linker region (Δ235–258,Δ235–297 andΔ258–297)
that inactivated HIV-1-restricting ability severely attenuated the
association with HIV-1 capsid complexes, whereas some capsid
binding was retained by the TRIM5αrh Δ235–247 mutant (Fig.
6C). Neither the TRIM5α RBCC nor the TRIM5α RBCC-L2
mutant appreciably bound HIV-1 CA–NC complexes (Fig. 6D).
To determine the contribution of TRIM5αrh trimerization to
HIV-1 capsid binding, the efficiencies of each of these
parameters, relative to those of the wild-type TRIM5αrh
Fig. 4. Dominant-negative activity of mutant TRIM5αrh proteins. (A) Lysates from Cf2Th cells stably coexpressing the V5-tagged CC proteins from various TRIM
family members and wild-type TRIM5αrh(HA) or wild-type TRIMCyp(HA) proteins were Western blotted and probed with an antibody directed against HA (upper
panel) or V5 (lower panel). (B) Cf2Th cells stably coexpressing the V5-tagged CC protein from various TRIM family members and wild-type TRIM5αrh(HA) (left
panel) or wild-type TRIMCyp(HA) (right panel) proteins were incubated with various amounts of HIV-1-GFP. Infected, GFP-positive cells were counted by FACS.
The results of a typical experiment are shown. Similar results were obtained in three independent experiments. (C) Transient transfection of 293T cells stably
expressing the TRIM5αrh protein was performed with plasmids expressing the indicated mutant TRIM5αrh proteins or trimeric GCN4, or with the pLPCX control
plasmid. Cells were incubated with various amounts of HIV-1-GFP. Infected, GFP-positive cells were counted by FACS. The results of a typical experiment are shown.
Similar results were obtained in three independent experiments.
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decreases in the efficiency of trimerization invariably exhibited
decreased ability to bind HIV-1 CA–NC complexes. These
results support a model in which TRIM5αrh trimerization is
important for capsid binding.
Discussion
In this paper, we document the requirement of the CC
domain for TRIM5αrh trimerization. Both the N-terminal CCA
and C-terminal CCB regions appear to contribute to efficient
trimerization of TRIM5αrh. Unlike the CC regions of other
TRIM proteins, the CC region of TRIM5 is not sufficient for the
formation of oligomers. The TRIM5α CC region apparently
requires flanking sequences, particularly the linker 2 (L2)region, for trimerization. The contribution of the L2 region to
TRIM5α oligomerization may involve effects of the L2 linker
on the coiled-coil conformation or the creation of independent
trimeric contacts involving L2.
The TRIM5αrh mutants that exhibited decreases in the ability
to trimerize also exhibited proportionate decreases in capsid
binding. This correlation supports the important contribution
that trimerization makes to capsid binding. TRIM5αrh likely
gains significant avidity for the retroviral capsid by virtue of the
trimeric state. Presumably, each of the B30.2(SPRY) domains is
positioned appropriately by TRIM5αrh trimerization to contact
its cognate binding site on the HIV-1 capsid. These results
support the hypothesis that TRIM5αrh represents an oligomer
that has evolved to interact efficiently with trimeric structures
on retroviral capsids.
Fig. 5. Effects of alterations of residues within the coiled coil on TRIM5αrh function and multimerization. (A) Cf2Th cells expressing the wild-type or mutant
TRIM5αrh proteins, or control Cf2Th cells transduced with the empty LPCX vector (Vector), were incubated with various amounts of HIV-1-GFP. Infected, GFP-
positive cells were counted by FACS. The results of a typical experiment are shown. Similar results were obtained in three independent experiments. (B) Lysates from
Cf2Th cells expressing wild-type or mutant TRIM5αrh proteins were cross-linked with increasing concentrations of EGS and were subjected to Western blotting with
an anti-HA antibody.
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coil, including a large number of changes involving hydrophilic
and charged residues, did not affect the efficiency oftrimerization or anti-HIV-1 activity. Presumably, these mutants
bind the HIV-1 capsid efficiently. Despite efficient trimeriza-
tion, the TRIM5αrh E197A/E198A and E220A/E222A mutants
Fig. 6. Specific association of TRIM5α variants with HIV-1 CA–NC complexes. (A–D) In vitro assembled CA–NC complexes were mixed with 293T lysates containing
wild-type TRIM5αrh-HA or the indicated TRIM5αrh-HA mutants and layered onto 70% sucrose before centrifugation. Immediately prior to mixing, an aliquot of the cell
lysate was removed and blotted with α-HA antibodies to determine the steady-state expression levels of the different TRIM5 variants (Input). After centrifugation, the pellet
was resuspended in SDS sample buffer and analyzed by Western blotting using an anti-HA antibody (to detect TRIM5) or an anti-p24 antibody (to detect CA–NC).
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infection, compared with the wild-type TRIM5αrh protein.
Subtle differences in the orientation of the trimers or the
relationship between the TRIM5αrh domains may be respon-
sible for these decreases. The inability of the TRIM5αrh ΔCC
GCN4 construct to bind HIV-1 capsid complexes or to inhibit
HIV-1 infection despite efficient trimerization supports the
concept that the coiled coil contributes more than oligomeri-
zation potential to TRIM5α structure.
Most full-length heterologous TRIM proteins do not
efficiently associate with TRIM5 (Reymond et al., 2001).
However, the coiled coils derived from multiple TRIM proteins
can exert dominant-negative activity on TRIM5αrh, probably
through coassociation during assembly or function. Conversely,
TRIM5αrh mutants lacking the coiled-coil domain also exhibited
some dominant-negative activity. Indeed, no single TRIM5αrh
domain appears to be absolutely required for dominant-negative
activity. This suggests that more than one TRIM5αrh domain canexert dominant-negative activity, perhaps involving multiple
mechanisms such as hetero-oligomer formation, competition for
capsid binding, or competition for cofactors.
Future studies should clarify the structural relationships
betweenTRIM5αdomains in the context of the functional trimer.
Materials and methods
Plasmid construction
The plasmids expressing the wild-type and mutant TRIM5αrh
proteins were constructed using PCR-directed mutagenesis. The
TRIM5αrh cDNAwas PCR-amplified (Stremlau et al., 2004) and
digested with EcoRI and ClaI, whose sites were introduced in
each of the PCR primers. These fragments were cloned into the
EcoRI and ClaI site of pLPCX (Stratagene). The plasmid
expressing TRIM5αrh-V5 was constructed by inserting a PCR-
amplified TRIM5αrh cDNA into the Viral Power plasmid using
Fig. 7. Contribution of TRIM5αrh trimerization to association with HIV-1 CA–
NC complexes. The relative ratios of trimer to monomer for the wild-type and
mutant TRIM5α proteins were calculated from the cross-linking experiments, at
an EGS concentration of 1 mM. The relative trimerization efficiency of each
TRIM5αrh variant was calculated by dividing the trimer/monomer ratio
observed for the variant by the trimer/monomer ratio observed for the wild-
type TRIM5αrh protein. The ratio of TRIM5α protein that cosedimented with
the HIV-1 capsid complexes to the amount of input TRIM5α protein was
calculated, and normalized to the ratio observed for the wild-type TRIM5αrh
protein to obtain relative HIV-1 CA/NC binding. The values for relative HIV-1
CA/NC binding were plotted as a function of trimerization efficiency. Error bars
represent the variation in the results of three independent experiments.
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structs from the different TRIM proteins contain the following
amino acid (a.a.) sequences: TRIM5αrh (a.a. 128–231),
TRIM5αHu (a.a. 128–233), TRIM1 (a.a. 208–314), TRIM6 (a.a.
125–234), TRIM21 (a.a. 124–228), TRIM22 (a.a. 130–230) and
TRIM27 (a.a. 128–238). The trimeric GCN4 protein sequence is:
MKQIEDKIEEIESKIKKIENEIARIKKLIGEG.
Creation of cells stably expressing TRIM5α variants
Retroviral vectors encoding wild-type or mutant TRIM5αrh
proteins were created using the pLPCX plasmid (Stremlau et al.,
2004). The LPCX vectors contain only the amino acid-coding
sequence of the TRIM5α cDNA. The TRIM5αrh proteins
encoded by the pLPCX vectors possess C-terminal epitope tags
derived from influenza hemagglutinin (HA). Recombinant
viruses were produced in 293T cells by cotransfecting the
pLPCX plasmids with the pVPack-GP and pVPack-VSV-G
packaging plasmids (Stratagene). The pVPack-VSV-G plasmid
encodes the vesicular stomatitis virus (VSV) G envelope
glycoprotein, which allows efficient entry into a wide range of
vertebrate cells. TRIM5αrh-V5 was made using the Viral Power
system (Invitrogen). The TRIM5αrh-V5 protein and other V5-
tagged variants possess aC-terminalV5 epitope tag.Recombinant
lentiviruses were produced according to the manufacturer's
protocol (Invitrogen). The resulting virus particles were used to
transduce approximately 1 × 106 Cf2Th cells in the presence of
5 μg/ml polybrene. Cells were selected in either 1 μg/ml
puromycin (Sigma) or 1 μg/ml puromycin and 2 μg/ml blasticidin
(Invitrogen).Infection with viruses expressing green fluorescent protein
(GFP)
Recombinant HIV-1, SIVmac and SIVagm expressing GFP
were prepared as described (Stremlau et al., 2004). HIV-1 viral
stocks were quantified by measuring reverse transcriptase (RT)
activity. For infections, 3 × 104 HeLa cells seeded in 24-well
plates were incubated in the presence of virus for 24 h. Cells
were washed and returned to culture for 48 h, and then subjected
to FACS analysis with a FACScan (Becton Dickinson).
Capsid-binding assay
Purification of recombinantly expressed HIV-1 CA–NC
protein from E. coli was carried out as previously described
(Ganser et al., 1999). High-molecular-weight HIV-1 capsid
complexes were assembled using 300 μM CA–NC protein and
60 μM (TG)50 DNA oligonucleotide in a volume of 100 μl of
50 mM Tris–HCl (pH 8.0) and 500 mM NaCl. The reaction was
allowed to proceed overnight at 4 °C, and the assembled CA–
NC complexes were stored at 4 °C until needed.
For a source of TRIM5 protein, 106 293T cells seeded in a 6-
well dish were transfected with 1 μg of the appropriate pLPCX-
TRIM5 plasmid, using Lipofectamine 2000. Forty-eight hours
later, the cells were harvested in PBS containing 5 mM EDTA
and resuspended in 250 μl of hypotonic lysis buffer (10 mM
Tris–HCl pH 8.0, 10 mM KCl, 1 mM EDTA) and placed on ice
for 15 min. The cells were lysed by using a 2-ml Dounce
homogenizer (PestleB,15 strokes) and the cell debris removedby
centrifugation at 4 °C for 10min at maximum speed (14,000 × g)
in an Eppendorf microfuge. Fifty microliters of lysate was saved
for assessment of the input amount of TRIM5 in the assay. Two-
hundred microliters of the cleared cell lysate was combined with
5 μl of HIV-1 CA–NC complexes from the assembly reaction
and the concentration of NaCl adjusted to 150 mM. The mixture
was incubated for 1 h at room temperature with gentle mixing.
After incubation, the mixture was layered onto a 2-ml 70%
sucrose cushion (prepared in 1× PBS) and centrifuged at
110,000 × g for 1 h at 4 °C in a Beckman SW55Ti rotor. The
pellet was resuspended in 50 μl of 1× SDS sample buffer and
subjected to SDS-PAGE and Western blotting. The ratio of
TRIM5α variant in the pellet, relative to the input TRIM5α
protein, was determined with a STORM system and a
PhosphorImager Screen (Molecular Dynamics).
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl;
1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS];
1% NP-40; 2 mg of aprotinin/ml; 2 mg of leupeptin/ml; 1 mg of
pepstatin A/ml; 100 mg of phenylmethylsulfonyl fluoride/ml).
The cell lysates were analyzed by SDS-PAGE (10% acrylam-
ide), followed by blotting onto nitrocellulose membranes
(Amersham Pharmacia Biotech). Detection of protein by
Western blotting utilized monoclonal antibodies that are
specifically reactive with the HA (Roche) or V5 (Invitrogen)
245H. Javanbakht et al. / Virology 353 (2006) 234–246epitope tags, and monoclonal antibodies to β-actin (Sigma).
Detection of proteins was performed by enhanced chemilumi-
nescence (NEN Life Sciences Products), using the following
secondary antibodies obtained from Amersham Pharmacia
Biotech: anti-mouse (for V5 and β-actin) and anti-rat (for HA).
Cross-linking
The HA-tagged and V5-tagged TRIM5 variants were
expressed transiently in 293T cells or stably in Cf2Th cells.
Cells were washed in phosphate-buffered saline (PBS) and lysed
in NP40 lysis buffer (0.5% Nonidet P40 (NP40), 1× protease
inhibitor (complete EDTA-free, Roche Diagnostics) in PBS) for
45 min at 4 °C. Lysates were centrifuged at 14,000 × g for 15 min
at 4 °C. The cleared lysates were not stored or frozen, but rather
were directly cross-linked. Approximately 100–200 μl of cleared
lysates were diluted with PBS/1 mM EDTA to a final volume of
400 μl. Lysates were cross-linkedwith varying concentrations (up
to 2 mM) of ethylene glycol-bis(succinimidyl succinate) (EGS)
for 30 min at room temperature and centrifuged briefly in a table-
top centrifuge. The reaction mix was quenched with 0.1 M Tris–
HCl, pH 7.5 and briefly centrifuged. The cleared, cross-linked
lysates were precipitated with the anti-HA antibody HA.11
(Covance) and protein A-Sepharose beads (Amersham) for 2 h at
4 °C; final volumes for the immunoprecipitationwere greater than
700 μl. The beads were washed four times with NP40wash buffer
(10mMTris–HCl, pH7.5, 0.5MNaCl, 0.5%NP40) and boiled in
LDS sample buffer (106 mM Tris–HCl, 141 mM Tris Base,
pH 8.5, 0.51 mM EDTA, 10% glycerol, 2% LDS, 0.22 mM
SERVA Blue G250, 0.175 mM phenol red (Invitrogen)) with
a final concentration of 1.2% β-mercaptoethanol (β-ME) for
10 min. Precipitated proteins were separated on 8% or 12%
Tris–glycine gels, transferred to a PVDF membrane, and
detected with the horseradish peroxidase-conjugated 3F10
anti-HA antibody (Roche Diagnostics) and the ECL Plus
Western Blotting Detection System (Amersham). The ratio of
cross-linked trimer and monomer was determined with a
STORM system and a PhosphorImager Screen (Molecular
Dynamics).
Immunoprecipitations
At 48 h after transfection, 293T cells were removed from the
plate and washed with PBS. 293T cells from nearly confluent
100-mm plates were lysed in 500 μl RIPA buffer. Insoluble
material was pelleted at 22,000 × g for 2 h and the supernatant
was used for immunoprecipitation. Equal amounts of protein
(approximately 200–500 μg, as determined by the BioRad
assay) were incubated with 30 μl protein A-Sepharose (50%)
and 5 μl of anti-HA antibody (Roche) for 2 h at 4 °C. The
immunoprecipitates were then washed three times with RIPA
buffer and twice with PBS. After the final supernatant was
removed, 30 μl of 2× sample buffer (120 mM Tris–HCl, pH 6.8,
20% glycerol, 4% SDS, and 0.02% bromphenol blue) was
added and the precipitate was boiled for 5 min to release the
precipitated proteins. After centrifugation, the resulting super-
natant was analyzed by SDS-PAGE and Western blotting.Immunofluorescence confocal microscopy
Cf2Th cells expressing the wild-type or variant TRIM5α
proteins were grown overnight on Lab-Tek II Chamber Slides
(Nalge Nunc International). Following fixation for 15 min in
Cytofix/Cytoperm (BD Biosciences) and permeabilization for
15 min in Perm/Wash (BD Biosciences), the cells were
incubated for 1 h with rat anti-HA 3F10 antibody (Roche).
The cells were then incubated with anti-rat IgG conjugated
with FITC (Santa Cruz) to detect the expression of the
TRIM5α protein, and examined by confocal fluorescence
microscopy.
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